Ferrarotto, R., Kaczmar, J. M., Spigel, D. R., Chung, C. H., Zandberg, D. P., Braña, I., Even, C., Harrington, K. J., Licitra, L. F., Keam, B., Rischin, D., Dalal, R. P., Raben, D., Salazar, R., Schulten, J., Hanna, G. J. (2025). A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: The FORTIFI-HN01 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps6113